Sector News

Valeant drops tainted name to become Bausch Health in July rebrand

May 9, 2018
Life sciences

Market watchers and Valeant investors have seen no shortage of changes at the company during its storied collapse. Now, the drugmaker is getting a new name to press ahead.

After reviewing the names of internal brands and new options, the company chose to go with Bausch Health Companies. In a statement, CEO Joseph Papa said the rebrand is part of a “major step forward in our transformation.”

Along with the name change will come a fresh brand identity, the company said. It’ll take the new moniker in July and trade under the ticker BHC.

Under mounting public relations and business pressures a year ago, Papa said Valeant was eyeing a name change. That followed former big investor William Ackman’s suggestion that the company could rebrand to help improve its reputation. Since that advice in November 2016, Ackman has bowed out of his Valeant investment, recording a $4 billion loss.

Valeant shares have lost more than 90% of their value from a high point of $257 in July 2015.

Bausch Health Companies is a nod to the company’s key brands of eye company Bausch & Lomb, picked up for $8.7 billion in 2013. Valeant was on an acquisition binge for years, racking up tens of billions of dollars in debt before its business model—including growth by M&A, huge price hikes and a murky specialty pharmacy relationship—came under fire. Congressional hearings, plus federal and state probes, followed.

Papa came on board in May 2016 and has worked to reduce the company’s debt to $25.44 billion at the end of 2017, down from more than $30 billion.

On Tuesday, after news of the name change, Valeant’s shares jumped 14%.

Meanwhile, the issue with Valeant’s relationship to now-defunct specialty pharmacy Philidor is playing out in court at the trial of former executives accused of enriching themselves at the expense of shareholders.

The company announced the name change alongside its first-quarter results on Tuesday. For the period, it generated $2 billion in sales, a 5% decrease from the same period last year. Its net loss for the quarter was $2.28 billion, which the company attributed to lower volumes for certain products, patent losses and goodwill impairment charges.

By Eric Sagonowsky

Source: Fierce Pharma

comments closed

Related News

May 17, 2024

With new partnership, Galapagos takes decentralized CAR-T manufacturing quest nationwide

Life sciences

Though Galapagos has undergone plenty of staff shake-ups and strategy revamps in recent years, the company is sticking strong to the CAR-T pivot first unveiled by CEO Paul Stoffels, M.D., following his arrival at the biotech from Johnson & Johnson in early 2022.

May 17, 2024

Sanofi invests €1 Billion to boost drug manufacturing in France

Life sciences

The new investment is expected to create more than 500 jobs and significantly strengthen France’s ability to control the production of essential medicines from start to finish, the company stated. According to Sanofi, this plan increases the amount Sanofi has committed to major projects in France since the Covid-19 pandemic to over €3.5 billion.

May 17, 2024

Lonza, busy with capacity upgrades and exec turnover, hints at CDMO industry rebound

Life sciences

A tough biotech funding environment and a downturn in COVID-related contracts has weighed heavily on CDMOs of all stripes in recent years. Now, with a new CEO waiting in the wings, Swiss manufacturing juggernaut Lonza is attempting to reassure the market that an industry stabilization is on the horizon.

How can we help you?

We're easy to reach